What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
By Holly Campbell | October 15, 2018
Pharmaceutical Research and Manufacturers of America (PhRMA) member companies today announced their commitment to providing more transparency about medicine costs to help patients make more...
Read More
Americans want to know more than just the list price of a medicine—and we’re answering their call
By Robert Zirkelbach | October 15, 2018
The biopharmaceutical industry is answering the call to provide more information about medicine costs. As innovators of life-saving therapies, we recognize the importance of giving people the...
Read More
Balancing innovation and competition in the biologics marketplace
By David Korn | October 11, 2018
Last month, I presented at the U.S. Food and Drug Administration’s (FDA) Public Hearing on Facilitating Competition and Innovation in the Biological Products Marketplace. The hearing was part of...
Read More
Report: Corporate venture capital is catalyzing groundbreaking biomedical innovation in the United States
By Anne McDonald Pritchett, PhD | October 10, 2018
Venture capital is increasingly becoming the growing force for financing biotech and other startups, fueling medical advances in the U.S. A new report released today from TEConomy, examines the...
Read More
ICYMI: Wall Street Journal highlights dangers of counterfeit medicines entering the United States through drug importation
By Nicole Longo | October 9, 2018
This week, the Wall Street Journal took a closer look at the very real threat drug importation poses, detailing how such schemes expose Americans to dangerous counterfeit medicines. The reporter...
Read More
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
By Katie Koziara | October 4, 2018
According to a new report by IQVIA Institute for Human Data Science, more and more patients are asked to pay high cost sharing due to changes in benefit design. Previous analysis has shown that...
Read More
Examining the truth behind clinical trial costs
By John Corea | October 2, 2018
Last week, a study appearing in the Journal of the American Medical Association (JAMA) Internal Medicine, evaluated the costs specifically associated with successful clinical trials for novel...
Read More
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
By Katie Koziara | October 2, 2018
Tomorrow, October 3, PhRMA will convene health care leaders for a discussion on how we can move our health care system toward one focused on value rather than volume, ensuring patients can access...
Read More
Safe and effective prescribing: A new and important initiative from the PhRMA Foundation
By Eileen Cannon | September 26, 2018
Safe and effective prescribing is a critically important part of the equation for successful medical treatment in today’s health care system. Yet data from the Association of American Colleges...
Read More
PhRMA comments in response to request for information on competitive bidding program in Medicare Part B
By Nicole Longo | September 25, 2018
Yesterday, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the recent 2019 Hospital Outpatient Prospective Payment System proposed rule,...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
